Overview

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

Status:
Active, not recruiting

Trial end date:
2022-05-19

Target enrollment:

Participant gender:

Summary

This study will assess the safety, efficacy, and pharmacokinetics of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST).

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo, Inc.